-
公开(公告)号：EP1051189A2
公开(公告)日：2000-11-15
申请号：EP99910158.7
申请日：1999-01-27
CPC分类号： A61K39/39 , A61K39/00 , A61K2039/55511
摘要： The invention relates to a vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants. The vaccine is presented as a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions. Said vaccine preferably contains substances able to make it isotonic, especially sorbitol.
-
公开(公告)号：EP0689604A1
公开(公告)日：1996-01-03
申请号：EP94911921.0
申请日：1994-03-18
发明人： BIRNSTIEL, Max L. , BUSCHLE, Michael , COTTEN, Matthew , MAAS, Gerhard , PLANK, Christian , SCHAFFNER, Gotthold , SCHMIDT, Walter , WAGNER, Ernst , ZATLOUKAL, Kurt
IPC分类号： C12N15 , A61K35 , A61K39 , A61K47 , A61K48 , A61P35 , A61P37 , C07K14 , C12N5 , C12N7 , C12P21 , C12Q1 , A61K38 , C12R1
CPC分类号： C12N7/00 , A61K38/00 , A61K39/0011 , A61K47/50 , A61K48/00 , C07K14/005 , C07K14/485 , C07K14/535 , C07K14/55 , C07K14/57 , C07K14/705 , C12N15/87 , C12N2710/10343 , C12N2710/10361 , C12N2760/20122 , C12Q1/701
摘要： Cancer vaccines are prepared by treating tumor cells or fibroblasts with a complex of immunostimulating polypeptide-coding DNA and of DNA-binding substance, for example polylysine, preferably conjugated with transferrine. The complex further contains a conjugate of DNA-binding substance and of an endosomolytic peptide or an adenovirus having at least one E4 defect or one E1a defect associated with other genetic defects.
-
3.发明授权
公开(公告)号：EP0881906B2
公开(公告)日：2009-02-04
申请号：EP97905068.9
申请日：1997-02-21
CPC分类号： A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/5154 , A61K2039/5156 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55566 , A61K2039/70 , C12N2760/16122 , C12N2760/16134 , A61K38/40 , A61K38/19 , A61K31/74 , A61K31/70 , A61K31/7004 , A61K39/0005 , A61K2300/00
摘要： The invention concerns a pharmaceutical composition containing at least one immunomodulating peptide or a protein (fragment) together with an adjuvant. The peptide is derived from a pathogen or a tumour antigen. The adjutant has the ability to increase the binding of the peptide to the cells of the individual to be treated or increase the absorption of the peptide by the cells and intensify the immunomodulating effect of the peptide. Preferred adjuvants are basic polyamino acids, such as polyarginine or polylysine, which are optionally conjugated with a cellular ligand, for example a carbohydrate group or transferrin. The composition is used in particular as a vaccine, for example a tumour vaccine.
-
4.发明授权
公开(公告)号：EP0881906B1
公开(公告)日：2004-08-25
申请号：EP97905068.9
申请日：1997-02-21
CPC分类号： A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/5154 , A61K2039/5156 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55566 , A61K2039/70 , C12N2760/16122 , C12N2760/16134 , A61K38/40 , A61K38/19 , A61K31/74 , A61K31/70 , A61K31/7004 , A61K39/0005 , A61K2300/00
摘要： The invention concerns a pharmaceutical composition containing at least one immunomodulating peptide or a protein (fragment) together with an adjuvant. The peptide is derived from a pathogen or a tumour antigen. The adjutant has the ability to increase the binding of the peptide to the cells of the individual to be treated or increase the absorption of the peptide by the cells and intensify the immunomodulating effect of the peptide. Preferred adjuvants are basic polyamino acids, such as polyarginine or polylysine, which are optionally conjugated with a cellular ligand, for example a carbohydrate group or transferrin. The composition is used in particular as a vaccine, for example a tumour vaccine.
-
5.发明公开
公开(公告)号：EP0881906A1
公开(公告)日：1998-12-09
申请号：EP97905068.0
申请日：1997-02-21
CPC分类号： A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/5154 , A61K2039/5156 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55566 , A61K2039/70 , C12N2760/16122 , C12N2760/16134 , A61K38/40 , A61K38/19 , A61K31/74 , A61K31/70 , A61K31/7004 , A61K39/0005 , A61K2300/00
摘要： The invention concerns a pharmaceutical composition containing at least one immunomodulating peptide or a protein (fragment) together with an adjuvant. The peptide is derived from a pathogen or a tumour antigen. The adjutant has the ability to increase the binding of the peptide to the cells of the individual to be treated or increase the absorption of the peptide by the cells and intensify the immunomodulating effect of the peptide. Preferred adjuvants are basic polyamino acids, such as polyarginine or polylysine, which are optionally conjugated with a cellular ligand, for example a carbohydrate group or transferrin. The composition is used in particular as a vaccine, for example a tumour vaccine.
-
公开(公告)号：EP0866851A1
公开(公告)日：1998-09-30
申请号：EP96939870.0
申请日：1996-11-21
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/39 , A61K2039/5154 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/585 , A61K2300/00
摘要： The invention relates to a tumour vaccine and a process for the preparation thereof. The tumour vaccine contains tumour cells, at least a portion of which has at least one MHC-I-haplotype of the patient on the cell surface, and which have been loaded in such a manner with one or a plurality of peptides bonding to the MHC-I-molecule that said tumour cells are recognised as foreign within the context of the peptides by the patient's immune system and trigger a cellular immune response. Loading takes place in the presence of a polycation such as polylysine.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
